Study of Etanercept in Subjects With Rheumatoid Arthritis Who Have Had an Inadequate Response to Adalimumab or Infliximab Plus Methotrexate (SERUM)

Pfizer logo

Pfizer

Status and phase

Terminated
Phase 4

Conditions

Rheumatoid Arthritis

Treatments

Drug: Etanercept
Drug: Placebo

Study type

Interventional

Funder types

Industry

Identifiers

NCT01783015
B1801355
2012-003644-71 (EudraCT Number)

Details and patient eligibility

About

The first 12 weeks of this study will compare the efficacy of etanercept 50 mg once-weekly to placebo in subjects with rheumatoid arthritis who have not responded well to infliximab or adalimumab plus methotrexate. This comparison will be performed for all subjects and separately for subjects who are anti-drug antibody positive for one of these medications. From week 12 to week 24, all subjects will receive etanercept 50 mg once-weekly. The effect of anti-drug antibody status on the efficacy of etanercept as well as the safety profile of etanercept in these subjects will also be evaluated throughout the study.

Full description

This study was prematurely terminated on June 25, 2014 due to significant and continuing delays in achieving the study B1801355 enrolment target. The decision to stop the study was not driven by any safety concerns.

Enrollment

16 patients

Sex

All

Ages

18 to 79 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Met the 1987 ACR Revised Criteria for RA
  2. A history of inadequate response to infliximab or adalimumab in combination with methotrexate.
  3. A stable dose of oral methotrexate for at least 6 weeks before the baseline visit.

Exclusion criteria

  1. ACR functional class IV
  2. Prior treatment with etanercept; both infliximab and adalimumab; or any immunosuppressive biologic agent other than infliximab or adalimumab.
  3. Discontinuation of infliximab or adalimumab for a primary reason other than inadequate efficacy response.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

16 participants in 4 patient groups, including a placebo group

Group A
Experimental group
Description:
Subjects who are mAb ADA positive
Treatment:
Drug: Etanercept
Group B
Experimental group
Description:
Subjects who are mAb ADA negative
Treatment:
Drug: Etanercept
Group C
Placebo Comparator group
Description:
Subjects who are mAb ADA positive
Treatment:
Drug: Placebo
Group D
Placebo Comparator group
Description:
Subjects who are mAb ADA negative
Treatment:
Drug: Placebo

Trial contacts and locations

15

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems